The mammalian target of rapamycin (mTOR) has emerged as a significant
The mammalian target of rapamycin (mTOR) has emerged as a significant therapeutic target for diffuse large B-cell lymphoma (DLBCL), as recent studies have demonstrated that 30% of relapsed patients react to mTOR inhibitors. may be the first demo a HDI such as for example LBH may overcome rapamycin level of resistance through a phosphatase that … [Read more…]